Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 72Gastrointestinal 29Thoracic 28Breast 23Head & Neck 19Genitourinary 18Dermatologic 11Other solid neoplasm 5Sarcoma 3Lymphoid 3Plasma cell 1NET 1Myeloid 1Endocrine 1

Conditions

Neuroendocrine Tumors 11Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Parotid Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Microsatellite Instability 1Mesothelioma 1Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Carcinoid Tumor 1Breast Neoplasms 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 1PM 01183 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × pembrolizumab × NET × Clear all
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡